Megan Stringer
YOU?
Author Swipe
View article: Sex-specific developmental alterations in DYRK1A expression in the brain of a Down syndrome mouse model
Sex-specific developmental alterations in DYRK1A expression in the brain of a Down syndrome mouse model Open
Aberrant neurodevelopment in Down syndrome (DS)-caused by triplication of human chromosome 21-is commonly attributed to gene dosage imbalance, linking overexpression of trisomic genes with disrupted developmental processes, with DYRK1A par…
View article: Evaluation of the therapeutic potential of Epigallocatechin-3-gallate (EGCG) via oral gavage in young adult Down syndrome mice
Evaluation of the therapeutic potential of Epigallocatechin-3-gallate (EGCG) via oral gavage in young adult Down syndrome mice Open
Epigallocatechin-3-gallate (EGCG) is a candidate therapeutic for Down syndrome (DS) phenotypes based on in vitro inhibition of DYRK1A, a triplicated gene product of Trisomy 21 (Ts21). Consumption of green tea extracts containing EGCG impro…
View article: Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits
Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits Open
Overexpression of Dual-specificity tyrosine-phosphorylated regulated kinase 1A (DYRK1A), located on human chromosome 21, may alter molecular processes linked to developmental deficits in Down syndrome (DS). Trisomic DYRK1A is a rational th…